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Ki-67 assessment in early breast 
cancer: SAKK28/12 validation study 
on the IBCSG VIII and IBCSG IX 
cohort
Zsuzsanna Varga  1, Qiyu Li2, Wolfram Jochum3, Ulrike Perriard4, Tilman Rau5, Jean-
Christoph Tille6, Hanne Hawle2, Dirk Klingbiel2, Beat Thuerlimann7 & Thomas Ruhstaller7
The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in 
planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-
responsive patients. An accurate determination of the Ki-67 index is of the utmost importance; 
however, the reproducibility is currently unsatisfactory. In this study, we addressed the predictive/
prognostic value of Ki-67 index assessed by using the most reproducible methods, which were identified 
in the pilot phase. Paraffin blocks obtained from patients with moderately differentiated, estrogen 
receptor (ER)-positive early-stage breast cancer in Switzerland, who were originally randomized to 
the treatment arms with and without chemotherapy in the IBCSG VIII-IX trials, were retrieved. Of 
these 344 randomized patients, we identified 158 patients (82 treated with and 76 treated without 
chemotherapy) for whom sufficient tumour tissue was available. The presence of Ki-67 was assessed 
visually by counting 2000 cells at the periphery (A) and estimating the number of positive cells in five 
different peripheral regions (C), which was determined to be the most reproducible method identified 
the pilot phase. The prognostic and predictive value was assessed by calculating the breast cancer-free 
interval (BCFI) and overall survival (OS) rate. Ki-67 was considered a numerical and categorical variable 
when different cut-off values were used (10%, 14%, 20% and 30%). An mRNA-based subtyping by using 
the MammaTyper kit with the application of a 20% Ki-67 immunohistochemistry (IHC) cut-off equivalent 
was also performed. 158 of 344 randomized patients could be included in the Ki-67 analysis. The mean 
Ki-67 values obtained by using the two methods differed (A: 21.32% and C: 16.07%). Ki-67 assessed 
by using method A with a cut-off of 10% was a predictive marker for OS, as the hazard ratio (>10% 
vs. <=10%) in patients with chemotherapy was 0.48 with a 95% confidence interval of [0.19–1.19]. 
Further, the HR of patients treated without chemotherapy was 3.72 with a 95% confidence interval 
of [1.16–11.96] (pinteraction=0.007). Higher Ki-67 index was not associated with outcome and using the 
10% Ki-67 cut-off there was an opposite association for patients with and without chemotherapy. Ki-67 
assessments with IHC significantly correlated with MammaTyper results (p=0.002). The exact counting 
method (A) performed via a light-microscope revealed the predictive value of Ki-67 assessment with 
a 10% cut-off value. Further analyses employing image analyses and/or mRNA-based-assessments in 
larger populations are warranted.
The assessment of proliferation by estimating the Ki-67 labelling index has increasingly become an integral 
biomarker of early-stage breast cancer1–13. The decision on further adjuvant hormonal therapy with additional 
chemotherapy in luminal A- and B-like breast cancers is based on the progesterone receptor status and Ki-67 
labelling index1–3,7,10,12–15. Recent indications for preoperative chemotherapy, including patients with luminal-type 
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breast cancers, increasingly include the Ki-67 labelling index as a biomarker for this therapy choice9,16,17. The 
issues of reproducibility and the choice of the best method for measuring the Ki-67 labelling index have been the 
subject of several pathology studies and were included in several oncological/senological guidelines4,5,8,11,18–28. 
Difficulties in reproducing the Ki-67 labelling index are particularly crucial in the intermediate range proliferative 
luminal B-like breast cancers, as published data are reaching a consensus on this delicate issue and advising cau-
tion with the use of this biomarker4,5,8,11,18–20,22–28. Data have accumulated and results supporting or refuting the 
superiority of a digital or visual analysis are approximately equal, basically suggesting that both methodologies 
can be applied for routine diagnostic purposes3,22,23,27–29.
We previously conducted a reproducibility study (SAKK 28/12 pilot phase) testing different Ki-67 methods 
using visual and digital analyses to identify the most reproducible method regarding intra- and inter-rater reli-
ability. In the SAKK 28/12 validation phase, the chosen methods from the pilot phase were subjected to further 
analysis using a prospective clinical cohort comprised of paraffin blocks obtained from patients who were initially 
enrolled in the IBCSG VIII and IX trials11,13,22–28,30,31.
The aim of this study was to correlate the immunohistochemical Ki-67 labelling index obtained using the 
two most reproducible methods from the SAKK 28/12 study with clinical data such as overall survival (OS) 
and the breast cancer-free interval (BCFI)27. Additionally, we determined the Ki-67 index with an mRNA-based 
assessment using MammaTyper and correlated the mRNA levels with OS and BCFI. The reason to include 
mRNA-based subtyping and Ki-67 mRNA values was the high interobserver reliability and interclass correlation 
reported previously in mRNA-based subtyping32.
Methods
Objectives of the study. The main goal of the validation phase of SAKK 28/12 is to determine the prog-
nostic/predictive value of Ki-67, which was assessed by using the most reproducible methods, as identified in the 
pilot phase (methods A and C), for predicting OS and BCFI27. In the pilot phase, two assessing methods resulted 
in an almost equally high inter-observer reliability, which were both chosen for further validation in this study. 
These methods were: A (exact counting as the original recommendation) and C (estimating resp. eyeballing in 
central and peripheral regions)27.
Additionally, we aim to assess the association between mRNA-based subtyping and assessments based on 
methods A/C. Furthermore, we are also interested in determining the associations between the Ki-67 mRNA 
level and OS/BCFI.
Materials and Methods
We retrieved residual paraffin blocks collected before study treatment from patients who were enrolled in the 
IBCSG VIII and IX studies and registered in Switzerland.
The designs of IBCSG Trials VIII and IX have been described in detail elsewhere33,34. IBCSG Trials VIII and 
IX were randomized clinical trials that compared the effectiveness of adjuvant endocrine therapy alone and 
sequential chemotherapy followed by endocrine therapy for node-negative invasive breast cancer among pre- 
and peri-menopausal (Trial VIII) and post-menopausal (Trial IX) women33,34. The breast cancer-free interval was 
defined as the length of time from the date of randomization to any invasive breast cancer relapse (including ipsi-
lateral or contralateral breast recurrence) or was censored at date of the last follow-up or death without relapse. 
OS was defined as the length of time from the date of randomization to death from any cause or censored at the 
last known date the patient was alive33,34.
Briefly, from 1990–1999, in Trial VIII, 1063 pre- and peri-menopausal women with node-negative early breast 
cancer were randomly assigned to endocrine therapy with 24 months of goserelin alone, six cycles of chemo-
therapy with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF), or a sequence of 6 cycles of 
CMF followed by 18 months of goserelin. Similarly, from 1988–1999, in Trial IX, 1669 eligible post-menopausal 
women were randomly assigned to endocrine therapy with 5 years of 20 mg of tamoxifen daily or 3 cycles of CMF 
followed by tamoxifen to complete 5 years therapy. In each trial, randomization was stratified according to the 
locally determined ER status. Patient follow-up, vital status and the date of any relapse or recurrence are recorded 
in the IBCSG database. The median follow-up from randomization in Trial VIII is 12 years and in Trial IX 13 
years33,34. Ethical approval was obtained in participating countries according to national regulations.
Originally, 660 patients in Switzerland, all with G2 tumors, were randomized in the IBCSG VIII and IX stud-
ies, and 344 of these patients met the inclusion criteria (as ER positive, G2). Clinical outcome data was avail-
able only for the patients who met the inclusion criteria in the study (Fig. 1). Paraffin blocks from 158 of 344 
Swiss patients were retrieved from the archives of Swiss pathology institutions and contained sufficient amounts 
of invasive breast cancer tissues; 82 of these patients were randomized to the treatment arm with chemother-
apy. Eight pathology institutions (University Hospital Lausanne, University Hospital Basel, University Hospital 
Bern, University Hospital Geneva, University Hospital Zurich, Cantonal Hospital St. Gallen, Cantonal Hospital 
Graubünden and Cantonal Hospital Locarno Switzerland) that originally participated the IBCSG VIII and 
IX studies provided paraffin blocks. Patients selected for this study had a moderately differentiated hormone 
receptor-positive breast cancer (with a negative Her2 status available in the original studies). Morphology was 
controlled by preparing a fresh haematoxylin-eosin (HE)-stained section to confirm the presence of invasive 
cancer available for further studies. Data on overall survival (OS) and the breast cancer-free interval (BCFI) were 
provided to the SAKK by the IBCSG.
This project is a part of a retrospective breast cancer study on archived human tissues and was approved by the 
Ethical Committee of the Canton Zurich (ZH-KEK-2012-553).
Immunohistochemistry for Ki-67. The Ki-67 status was analysed using immunohistochemical stain-
ing, as described previously27. Briefly, sections for Ki-67 were stained centrally in the Institute of Pathology and 
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Molecular Pathology, University Hospital Zurich Switzerland according to the following laboratory protocol (the 
protocol is from the Institute of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland, 
Laboratory for in situ technology): Two micrometer thick sections were freshly cut from paraffin blocks con-
taining a sufficient amount of invasive carcinoma tissue. Ki-67 staining was performed using the fully automated 
Benchmark staining system (Ventana Medical Systems) and the primary antibody (rabbit monoclonal anti-Ki-67 
human, clone 30-09 Ventana Medical Systems, Inc.).
Interpretation of Ki-67 Immunohistochemistry. As discussed in the pilot phase of the study, the most 
reproducible methods were applied to this cohort and were conducted by the principle investigator (ZV) of this 
study, who was blinded to the clinical outcome (OS/BCFI) and performed the evaluations via a light micro-
scope27. The assessment methods designated as the best methods were method A (exact counting) and method C 
(eyeballing). Both methods were scored by the principle investigator (ZV).
Method A was defined as the original method of counting 2000 invasive cells in randomly selected, high-power 
magnification (400×) fields at the periphery of the tumor and determining the percentage of Ki-67 staining12.
Method C was defined as an estimating (so-called eye-balling) assessment analysis performed via a light 
microscope at 20× magnification for five random fields within the tumor (both the periphery and center), which 
included approximately 500 cells.
Digital analysis was not applied in this study, as none of the digital analysis methods investigated in the pilot 
phase outperformed the best light microscopic methods, methods A and C, in terms of reproducibility.
Ki-67 values are reported as percentages of the invasive tumour cells. Throughout this paper, the percent sym-
bol will be removed for Ki-67 index to simplify the presentation. Therefore, the Ki-67 index measured by using 
methods A and C are presented as a number ranging from 0 to 100.
Assessment of the Ki-67 mRNA. All 158 paraffin blocks underwent an assessment of the Ki-67 mRNA 
using the MammaTyper assay, as described previously32. Briefly, ten micrometer thick, unstained slides were 
freshly cut from the paraffin blocks at the Institute of Pathology and Molecular Pathology of the University 
Hospital Zurich and were sent to BioNTech Diagnostics GmbH, Mainz, Germany for the MammaTyper anal-
yses. The mRNA was extracted from the unstained slides with the RNXtract RNA Extraction Kit (BioNTech 
Diagnostics) and was subsequently measured via the MammaTyper analysis using the same technical procedures 
described in a previous study32. The mRNA analysis was blinded to the values of the Ki-67 immunostaining and 
the clinical outcome. The results were obtained from 137 paraffin blocks for the study. The remaining 21 blocks 
were excluded either due to a low RNA content because of a poor tissue quality or to missing clinicopathological 
information.
Interpretation of the Ki-67 mRNA assessment. As described above, MammaTyper is a molecular in 
vitro diagnostic test for the quantitative detection of the mRNA expression of the ERBB2 (HER2), ESR1 (ER), 
PGR (PR) and MKI67 (marker of proliferation Ki-67) genes. The test is used for the molecular subtyping of 
breast cancer tissue into the intrinsic subtypes Luminal A-like, Luminal B-like (HER 2-positive or -negative), 
HER2-positive (non-luminal) and Triple negative (ductal), as defined in the St. Gallen Consensus Conference 
recommendations utilized since 20111,7,14. The immunohistochemistry cut-off for the differentiation between 
Luminal A-like and Luminal B-like cancers was prospectively set to 20%, and the MammaTyper kit was designed 
using this cut-off based on the mRNA values32.
Statistical analysis. To assess the prognostic value of Ki-67 regarding to time-to-event endpoints (OS and 
BCFI), a Cox regression model with Ki-67 as the only covariable was fitted. To assess the predictive value of 
Ki-67, a Cox regression model including the Ki-67 index, treatment and the interaction of these two parameters 
Figure 1. Flow-chart diagram of patients and sample selection from IBCSG VIII and IX trials.
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was fitted. P values were calculated for these models by using Wald’s test. For additional research objectives, the 
Wilcoxon test was used to identify the association between Ki-67 index assessed by using methods A/C and the 
Ki-67 mRNA, while the log-rank test was used to assess the associations between the Ki-67 mRNA and OS/BCFI. 
The sample size estimation based on the prognostic value of Ki-67 (assessed by using method A) for BCFI was 
performed before we received the clinical data from IBCSG and retrieved the residual paraffin blocks. Assuming a 
rate of BC recurrence of 20%, a Cox regression analysis of Ki-67 with a standard deviation of 7.5 (estimated from 
the pilot phase of this project) based on a sample of 231 observations achieves 80% power at a 0.05 significance 
level to detect a hazard ratio of 1.25 and the number of observations accordingly.
PASS 11 was used to calculate the sample size. SAS 9.4 and R 3.3.2 were used for the analyses. Multiple test cor-
rections were not applied to all p values; thus, the results are considered exploratory. The motivation to select the 
specific Ki-67cut-offs as 10,14,20,30 was based on previously published consensus recommendations1–3,7,10,12–15.
Novelty and Impact statement. Our data draws attention to the fact that Ki-67 cut-off values are method-
ology and observer dependent, and median Ki-67 values can vary depending on the assessment methods. In our 
study, the exact counting under a light microscope revealed the predictive relevance of Ki-67 assessment using a 
10% cut-off value for predicting OS or BCFI.
Ethical approval and consent to participate. Ethical approval and informed consent from all patients 
to use the paraffin blocks at the time of IBCSG VIII and IX randomization were obtained according to the 
national regulations. The retrospective study was approved by the Lead Ethical Committee of the Canton Zurich 
(ZH-KEK-2012-553). All procedures performed in this study were conducted in accordance with the ethical 
standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and its 
later amendments or comparable ethical standards.
Consent for publication. All authors, as well the SAKK and the IBCSG scientific committees, read and 
approved the manuscript prior to submission. The study, including the design and data interpretation, was dis-
cussed during the SAKK annual and semiannual meetings.
Results
Summary. 158 of 344 Swiss patients randomized in the IBCSG BIG VIII and IX trials with G2 hormone 
receptor-positive and Her2-negative breast cancer and with available tumor tissue in paraffin blocks were 
included in this study (Fig. 1). Our results show, as described in details below, that different Ki-67 assessment 
methodologies have different mean and median values and the methodologies influence the correlation between 
OS/BCFI and Ki-67 labelling index. We could demonstrate, that a cut-off of 10% using visual Ki-67 IHC assess-
ment was a predictive marker of OS in patients who were not treated with chemotherapy. Moreover, we found that 
Ki-67 IHC assessments significantly correlated with Ki-67 mRNA measurements.
Descriptive analysis of Ki-67 immunohistochemistry and clinical outcomes. Mean and median 
Ki-67 values obtained using immunohistochemical Methods A and C. Compared with Method C (mean=16.07 
and median=10.00), Method A (mean=21.32 and median=17.70) generally produces a higher Ki-67 value. 
Range for Ki-67 values in both Method A and C was 1.00 to 90.00. These differences are shown in Fig. 2 as box-
plots (A) and in Fig. 2 as a Bland-Altman plot (B).
Frequencies of Ki-67-positive immunohistochemistry using different cut-off values. Using 10, 14, 20 and 30 as 
cut-off values for Ki-67 staining, the frequencies obtained by using different cut-offs differed between Methods 
A and C, as shown in Table 1.
Summary statistics of OS and BCFI. The two clinical endpoints were OS and BCFI, which were collected from 
the Swiss patients in the IBCSG VIII and IX studies, and these values are presented in Table 2. These endpoints 
Figure 2. (A) Boxplots of Ki-67 levels assessed by using Methods A and C. (B) Bland-Altman plot of Methods 
A and C.
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show 20 events in the subgroup with chemotherapy and 16 and 17 events, respectively, in the group without 
chemotherapy.
Estimated OS and BCFI probabilities. Patients in this Swiss collective enrolled in both treatment arms have 
similar outcomes as the entire IBCSG study population in terms of OS and BCFI. Estimated OS and BCFI prob-
abilities are shown in Fig. 3(A,B).
Prognostic value of Ki-67 immunohistochemistry assessed by using Method A for determining OS/BCFI. Based on 
the estimated HR, a higher Ki-67 value did not result in significantly higher hazard ratio for OS and BCFI (all p 
values are greater than 0.05).
In Table 3A, we present the HR estimated using the univariate Cox regression model, which utilizes Ki-67 
index assessed by using Method A as a numeric variable (the first row of the table) and a categorical variable based 
on different cut-off values (the second to fifth rows).
Prognostic value of Ki-67 immunohistochemistry assessed by using Method C for determining OS/BCFI. In 
Table 3B, we present the HR estimated using the univariate Cox regression model with Ki-67 index assessed by 
using Method C as the numeric variable (the first row of the table) and a categorical variable based on different 
cut-off values (the second to fifth rows).
Notably, the HRs, 95% CIs and p values based on cut-off values of 10 and 14 are exactly the same due to the 
lack of a Ki-67 index when assessed by using Method C at cut-off values ranging from 10 to 15 (see Fig. 2(A)). 
Therefore, samples with Ki-67 levels equal or less than 14 are exactly the same as samples with Ki-67 levels equal 
or less than 10.
Predictive value of Ki-67 immunohistochemistry assessed by using Method A for determining OS. By using the 
cut-off of 10% and Method A, we found significant differences in the OS and predictive value at levels below and 
above this threshold (p=0.0074). The use of the cut-off of 14% almost reached statistical significance and showed 
only a trend towards an improved OS (p=0.0554). No other cut-off values produced significant differences. In 
Figure 3. (A) Estimated overall survival (OS) probabilities. Patients in this cohort have similar outcomes in 
terms of OS. (B) Estimated breast cancer-free interval (BCFI) probabilities. Patients in this cohort have similar 
outcomes in terms of BCFI.
Cut-offs
Method A (N=158) Method C (N=158)
Nr. of pat. with
Ki-67 ≤ cut-off
Nr. of pat. with
Ki-67> cut-off
Nr. of pat. with
Ki-67 ≤ cut-off
Nr. of pat. with
Ki-67> cut-off
10 57 (36%) 101 (64%) 81 (51%) 77 (49%)
14 69 (44%) 89 (56%) 81 (51%) 77 (49%)
20 91 (56%) 67 (42%) 120 (76%) 38 (24%)
30 114 (72%) 44 (28%) 146 (92%) 12 (8%)
Table 1. Frequencies of Ki-67 using different cut offs.
Clinical 
endpoints
With Chemotherapy Without Chemotherapy
N
Number of 
events
Median
[95% CI] N
Number of 
events
Median
[95% CI]
OS (in years) 82 20 16.9 [16.2, NA] 76 16 16.8 [15.9, NA]
BCFI (in years) 82 20 Not reached 76 17 Not reached
Table 2. Summary statistics of OS and BCFI. Abbreviations: OS: overall survival, BCFI: breast cancer free 
interval.
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Table 4(A), we separately presented the HRs and 95% CIs estimated using the univariate Cox regression model of 
OS with Ki-67 levels assessed by using Method A for the two treatment groups. The p value (*p value) presented 
in Table 4(A) was calculated for the interaction term based on the multivariate Cox regression model of OS with 
Ki-67, treatment group and their interaction. Notably, Tables 4(B) and 5 present the data in the same manner. 
In Fig. 4(A), the OS is stratified by different cut-off values for Ki-67 which were assessed by using Method A and 
considering treatment allocation. Based on the estimated HR presented in Table 4(A) a higher Ki-67 level (>10%) 
results in a lower hazard ratio (HR 0.48) for OS in patients treated with chemotherapy. For patients who were 
not treated with chemotherapy, the opposite effect was observed (HR 3.72). These data show that patients with 
Ki-67<=10% do not profit from chemotherapy and patients with Ki-67>10% might potentially have a benefit. 
Using 10% as the cut-off, this effect was statistically significant.
Predictive value of Ki-67 immunohistochemistry assessed by using Method A for determining the BCFI. Ki-67 
levels assessed by using Method A did not show a significant ability to predict BCFI in patients stratified by treat-
ment allocation, as shown in Table 4(B) and Fig. 4(B).
Predictive value of Ki-67 immunohistochemistry assessed by using Method C for determining OS. Ki-67 levels 
assessed by using Method C did not display a significant ability to predict OS in patients stratified by treatment 
allocation, as shown in Table 5(A) and Fig. 5(A). However, there was a similar tendency for Method C compared 
to Method A with respect to OS.
Predictive value of Ki-67 immunohistochemistry assessed by using Method C for determining BCFI. Ki-67 levels 
did not display a significant ability to predict BCFI in patients stratified by treatment allocation, as shown in 
Table 5(B) and Fig. 5(B).
Correlation between Ki-67 immunohistochemistry and the mRNA-dependent luminal subtype assessment. A sig-
nificant correlation was observed between the immunohistochemical assessments (methods A and C) and the 
classification of the intrinsic subtypes as Luminal A-like or Luminal B-like with the MammaTyper kit: Range for 
Ki-67 values in both Method A and C was 1.00 to 90.00. As shown in Fig. 6, patients with MammaTyper Luminal 
B-like tumours generally presented higher Ki-67 values in IHC than patients with the Luminal A-like subtype.
Correlation between Ki-67 mRNA-dependent Luminal A- and Luminal B-like subtypes and OS/BCFI. In this 
cohort, we did not identify any significant correlations between OS/BCFI and the Ki-67 mRNA assessment, as 
shown in Fig. 7. Notably, the MammaTyper Ki-67 mRNA cut-off corresponds to a 20% IHC cut-off, which was 
not significant in this cohort, as shown above and determined by using IHC.
Discussion
In the SAKK 28/12 validation phase, we analysed the prognostic and predictive value of Ki-67 immunohisto-
chemistry assessed by using the most reproducible methods selected from the pilot phase of SAKK 28/1227. The 
old, archived paraffin blocks containing breast cancer tissues from patients in the IBCSG VIII and IX clinical 
trials and treated at the time of the trials in Switzerland were used in this study, and the corresponding clinical 
outcomes were also used for this project27,30,31. The median follow-up from randomization in Trial VIII was 12 
years and in Trial IX was 13 years33,34. Additionally, we also assessed Ki-67 mRNA levels and analysed the asso-
ciation with clinical outcomes, as we reported in an earlier paper, and Ki-67 mRNA levels are found to be highly 
reproducible32.
As shown in the present study, a Ki-67 index obtained using immunohistochemical method A (exact counting 
of tumour cells at the tumour periphery) with a cut-off of 10% predicts the OS of patients treated with chemo-
therapy. Although other results regarding the predictive and prognostic values were not statistically significant, 
(A) Variable Method A
OS BCFI
HR (95% CI) P value HR (95% CI) P value
Ki-67_A 1.01 (0.99–1.02) 0.54 1.01 (0.99–1.03) 0.20
Ki-67_A (>10 vs. <=10) 1.16 (0.58–2.33) 0.66 1.69 (0.82–3.50) 0.15
Ki-67_A (>14 vs. <=14) 1.20 (0.61–2.34) 0.59 1.54 (0.79–3.04) 0.20
Ki-67_A (>20 vs. <=20) 1.02 (0.53–1.98) 0.94 1.50 (0.79–2.86) 0.21
Ki-67_A (>30 vs. <=30) 1.02 (0.49–2.13) 0.94 1.16 (0.57–2.35) 0.68
(B) Variable Method C
OS BCFI
HR (95% CI) P value HR (95% CI) P value
Ki-67_C 1.00 (0.98–1.03) 0.87 1.01 (0.99–1.03) 0.47
Ki-67_C (>10 vs. <=10) 0.76 (0.39–1.48) 0.42 0.91 (0.48–1.74) 0.77
Ki-67_C (>14 vs. <=14) 0.76 (0.39–1.48) 0.42 0.91 (0.48–1.74) 0.77
Ki-67_C (>20 vs. <=20) 1.48 (0.71–3.09) 0.29 1.37 (0.66–2.84) 0.39
Ki-67_C (>30 vs. <=30) 0.99 (0.30–3.22) 0.98 1.23 (0.38–4.03) 0.73
Table 3. Prognostic value of Ki-67 assessed by Method A (A) and by Method C (B). Abbreviations: OS: overall 
survival, BCFI: breast cancer free interval.
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Ki-67 levels measured by using Method A represent a potential prognostic factor for BCFI based on the estimated 
HRs and confidence intervals, which indicated a higher risk of recurrence in patients with higher Ki-67 levels.
The identification of the optimal method or methodologies for the assessment of proliferative activity in breast 
cancer has been the subject of several previous studies in the last decade since the introduction of Ki-67 as a 
routinely assessed parameter in hormone receptor-positive breast cancer specimens1–12. These studies analysed 
different types of visual assessments and digital analyses to test whether one method outperforms the other or 
if these methods yield the same results in terms of reproducibility1–6,8,9,11–14. Based on the currently available 
published data, a trend that both visual and digital analyses result in a similar inter-rater coefficient has been 
observed, enabling the diagnostic use of both approaches9,15–19. However, the optimal methodology for assessing 
Ki-67 levels in breast cancer that fulfils the criteria of perfect inter-rater and inter-laboratory reproducibility has 
not yet been identified4,6,8,10,13,19,23,27. In contrast to midrange proliferative cancers where reproducibility remains 
an issue, the inter-rater reliability is considerably better for low and high proliferative cancers4,6,8,10,11,13,19,23,27. 
Intra-tumour heterogeneity and the area chosen for the Ki-67 assessment appear to be the most crucial factors, 
in addition to pre-analytical inter-laboratory differences at the current time4–6,8,10,13,19,23,27. This heterogeneity 
remains a relevant factor for Ki-67 and gene-signature tests.
The first descriptions of utilizing cut-off values with Ki-67 levels to make clinical decisions and to estimate 
prognosis were derived from Ki-67 measurements obtained from tumour samples in the IBCSG VIII and IX 
prospective clinical trials1,2,7,12,14,17,35.
One of the first sources of data on Ki-67 power measured in the IBCSG VIII and IX trials showed that the 
Ki-67 labelling index does not predict a benefit from adding chemotherapy to endocrine therapy but, rather, 
indicates a worse disease-free survival rate regardless of the treatment modalities and, thus, provides important 
prognostic information35.
The median Ki-67 values, as assessed by central pathology, for tumours in IBCSG VIII and IX were 19%35.
Since the original description in 2008, which stated that a cut-off of 14% for the Ki-67 level differentiates 
between Luminal A and Luminal B tumours, the cut-off value has periodically undergone adjustments, such 
as shifting from 20% to 30% or being described as simply low and high, depending on the midrange Ki-67 
(A) Variables OS
HR (95% CI)
P valueWith Chemotherapy Without Chemotherapy
Ki-67_A 0.99 (0.95–1.02) 1.02 (1.00–1.04) 0.12
Ki-67_A (>10 vs. <=10) 0.48 (0.19–1.19) 3.72 (1.16–11.96) 0.0074
Ki-67_A (>14 vs. <=14) 0.67 (0.27–1.68) 2.64 (0.93–7.52) 0.0554
Ki-67_A (>20 vs. <=20) 0.64 (0.26–1.58) 2.02 (0.75–5.47) 0.094
Ki-67_A (>30 vs. <=30) 0.73 (0.27–2.03) 1.60 (0.55–4.62) 0.29
(B) Variables BCFI
HR (95% CI)
P value
With Chemotherapy Without Chemotherapy
Ki-67_A 1.01 (0.98–1.04) 1.01 (0.99–1.03) 0.84
Ki-67_A (>10 vs. <=10) 1.23 (0.45–3.38) 2.31 (0.81–6.62) 0.39
Ki-67_A (>14 vs. <=14) 1.82 (0.66–5.01) 1.34 (0.52–3.50) 0.67
Ki-67_A (>20 vs. <=20) 1.45 (0.60–3.51) 1.55 (0.59–4.01) 0.92
Ki-67_A (>30 vs. <=30) 1.24 (0.50–3.13) 1.05 (0.34–3.22) 0.81
Table 4. Predictive value of Ki-67 assessed by Method A on OS (A) and on BCFI (B). Abbreviations: OS: overall 
survival, BCFI: breast cancer free interval.
(A) Variables OS
HR (95% CI)
P valueWith Chemotherapy Without Chemotherapy
Ki-67_C 0.98 (0.94–1.03) 1.01 (0.98–1.04) 0.34
Ki-67_C (>10 vs. <=10) 0.48 (0.20–1.19) 1.45 (0.53–3.99) 0.11
Ki-67_C (>14 vs. <=14) 0.48 (0.20–1.19) 1.45 (0.53–3.99) 0.11
Ki-67_C (>20 vs. <=20) 0.89 (0.29–2.71) 2.37 (0.86–6.54) 0.21
Ki-67_C (>30 vs. <=30) 0.98 (0.13–7.39) 0.97 (0.22–4.30) 0.96
(B) Variables BCFI
HR (95% CI)
P value
With Chemotherapy Without Chemotherapy
Ki-67_C 1.01 (0.96–1.05) 1.01 (0.98–1.03) 0.88
Ki-67_C (>10 vs. <=10) 1.01 (0.42–2.44) 0.78 (0.29–2.12) 0.68
Ki-67_C (>14 vs. <=14) 1.01 (0.42–2.44) 0.78 (0.29–2.12) 0.68
Ki-67_C (>20 vs. <=20) 1.08 (0.39–2.97) 1.77 (0.62–5.03) 0.48
Ki-67_C (>30 vs. <=30) 1.58 (0.21–12.05) 1.11 (0.25–4.88) 0.83
Table 5. Predictive value of Ki-67 assessed by Method C on OS (A) and BCFI (B). Abbreviations: OS: overall 
survival, BCFI: breast cancer free interval.
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levels measured at a specific pathology institution, and these modifications are still underway even curren
tly1,2,4,6,8,11,13,19,23,27. This change is probably one reason why our study used a lower optimal and significant Ki-67 
cut-off value (10%) to assess overall survival, although the median Ki-67 level was 17.7% for method A. Further 
explanations for our discrepancy from the original definition of 14% are most likely the smaller sample size and 
the observation of fewer events in both arms of the Swiss subset of the IBCSG VIII and IX cohorts, although 
applying a 14% cut-off value with Method A almost reached statistical significance in this subset.
The difficulties in defining the optimal cut-off value and the most reproducible Ki-67 assessment methods 
has led to adjustments in the clinical guidelines as well, as the current recommendations of the St. Gallen 2017 
Consensus Conference do not include cut-offs but instead state that low and high Ki-67 categories, in accordance 
with the midrange Ki-67 values of the specific pathology laboratory, should be applied1,2,8,10,13,19,23,27. Nevertheless, 
Figure 4. (A) Kaplan-Meier curves show the analyses of the overall survival (OS) of patients stratified by 
different cut-off values for Ki-67 levels, as measured using Method A and considering treatment allocation. (B) 
Kaplan-Meier curves show the analysis of the breast cancer-free interval (BCFI) in patients stratified by different 
cut-off values for Ki-67 levels measured using Method A and considering treatment allocation.
Figure 5. (A) Kaplan-Meier curves show differences in the overall survival (OS) of patients stratified by 
different cut-off values for Ki-67 levels measured using Method C and considering treatment allocation. (B) 
Kaplan-Meier curves show differences in the breast cancer-free interval (BCFI) in patients stratified by different 
cut-off values for Ki-67 levels measured using Method C and considering treatment allocation.
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Ki-67 levels greater than 20–25, regardless of the assessment methodology, are probably the best approximate 
cut-off values to estimate risk of death compared to lower values and to decide whether additional adjuvant 
chemotherapy should be administered2,12.
Alternative methods to immunohistochemical Ki-67 assessments, such as mRNA-based analyses, were recom-
mended in recent studies, as inter-laboratory reproducibility with ICC values of 0.980–0.998 revealed the excel-
lent agreement of quantitative measurements for Ki-67 levels measured using MammaTyper13,32. Another recent 
mRNA-based study assessing Ki-67 levels with STRAT4 showed a good correlation with Ki-67 immunohistochemis-
try at a 30% cut-off36. However, the clinical utility, particularly in the intermediate range, has not yet been confirmed.
In the present study, Ki-67 IHC assessed by using methods A and C correlated well with the mRNA-based 
assessments of Luminal A-like and Luminal B-like (HER2 negative) tumours, although Methods A and C pro-
duced different Ki-67 values, namely, mean values of 21.3 and 16.1, respectively. This observation has been 
reported in recent studies, showing that different assessment methodologies using both visual and digital 
Figure 6. A significant correlation was observed between the immunohistochemical Ki-67 assessments 
(methods A and C) and classification with the Ki-67 mRNA-dependent Luminal A- and Luminal B-like intrinsic 
subtypes using MammaTyper.
Figure 7. Correlation between overall survival (OS), breast cancer-free interval (BCFI) and the Ki-67 mRNA-
dependent Luminal A- and Luminal B-like intrinsic subtype assessment with MammaTyper (the results were not 
statistically significant).
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measurements result in different mean and median Ki-67 levels4–6,23,28,37,38. The lack of any significant correlations 
between the mRNA-based Ki-67-dependent Luminal A-like and Luminal B-like subtype assessment and OS/BCFI 
in our study is probably due to the smaller sample size in the Swiss cohort and the focus on grade 2 tumours, 
which is in contrast to the entirety of the IBCSG VIII and IX clinical trials. Within this restricted cohort, only the 
10% Ki-67 IHC cut-off reached significance, while the MammaTyper MKI67 cut-off correlated with a 20% Ki-67 
cut-off. Furthermore, intra-tumour heterogeneity and the analysis of different tumour areas in different tumour 
blocks from the same tumour of each patient differed from the analyses applied in the original IBCGS VIII and 
IX subsets and should be considered when interpreting divergent results.
The question of the optimal tissue, such as biopsy, surgical specimen or tissue-micro-arrays (TMA), to assess 
the Ki-67 index in breast cancer is controversial and has been addressed in the literature9,10,25,26,37–39. As shown in 
several previous studies, Ki-67 levels obtained from the same tumour, whether obtained via TMA, core biopsy or 
surgical specimen, differ due to intra-tumour heterogeneity, which must be considered in clinical practice if dif-
ferent tissue specimens are available37–39. In our study, we restricted the analysis to surgical specimens, which was 
similar to the original IBCSG VIII and IX cohorts. Nevertheless, in daily routine pathological diagnostics, core 
biopsies are increasingly considered the primary source for Ki-67 assessments regarding both adjuvant therapy 
decisions and preoperative chemotherapy selection3,8,10,16,17. As described above, optimal Ki-67 cut-off values in 
core biopsies for predicting the response to preoperative chemotherapy range from 15–30%3,16,17,40.
Conclusions
In summary, different Ki-67 assessment methodologies affect the correlations with overall survival and the breast 
cancer-free interval in patients with moderately differentiated breast cancer. Based on our results, method A 
(counting cells using visual assessment) using a cut-off of 10% was a predictive marker of OS in patients who were 
not treated with chemotherapy. Higher Ki-67 index was not associated with outcome and using the 10% Ki-67 
cut-off there was an opposite association for patients with and without chemotherapy.
The results in this study are hypothesis generating and additional validation of these finding appears war-
ranted. The issue of Ki-67 assessment in breast cancer in terms of the methodology and optimal cut-off values, 
particularly in midrange samples, remains a challenge, and further studies analysing correlations and prospective 
clinical trials are needed.
Data Availability
All data and study materials are available upon request without any restrictions.
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